Victoza Approval History

• FDA approved: Yes (First approved January 25th, 2010)
• Brand name: Victoza
• Generic name: liraglutide
• Dosage form: Injection
• Company: Novo Nordisk
• Treatment for: Diabetes, Type 2

Victoza (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of heart attack, stroke and CV death in adults with type 2 diabetes and established CV disease.

Development History and FDA Approval Process for Victoza

Date	Article
Aug 25, 2017	Victoza (liraglutide) is Approved to Reduce the Risk of Three Major Adverse Cardiovascular Events in Type 2 Diabetes Patients
Apr  9, 2012	Victoza Label Updated to Include Data Showing Superior Efficacy When Compared to Januvia
Jan 26, 2010	FDA Approves Novo-Nordisk's Diabetes Drug Victoza
Apr  3, 2009	Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes
May 30, 2008	Novo Nordisk Files for Regulatory Approval of Liraglutide in Both the US and Europe

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.